Pulmatrix Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| PULMATRIX, INC. | ||
| Date: March 28, 2024 | By: | /s/ Teofilo Raad |
|---|---|---|
| Teofilo Raad | ||
| Chief Executive Officer and President | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Teofilo Raad | Chief Executive Officer, President and Director (Principal Executive Officer) | March 28, 2024 |
| Teofilo Raad | ||
| /s/ Peter Ludlum | Interim Chief Financial Officer | March 28, 2024 |
| Peter Ludlum | (Principal Financial and Accounting Officer) | |
| /s/ Michael J. Higgins | Chairman of the Board of Directors | March 28, 2024 |
| Michael J. Higgins | ||
| /s/ Richard Batycky, Ph.D. | Director | March 28, 2024 |
| Richard Batycky, Ph.D. | ||
| /s/ Todd Bazemore | Director | March 28, 2024 |
| Todd Bazemore | ||
| /s/ Christopher Cabell, M.D. | Director | March 28, 2024 |
| Christopher Cabell, M.D. | ||
| /s/ Anand Varadan | Director | March 28, 2024 |
| Anand Varadan | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 688) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.